CASSAVA SCIENCES INC

Clinical-stage biotech developing oral drug simufilam for CNS disorders like TSC-related epilepsy.

SAVA | US

Overview

Corporate Details

ISIN(s):: US69562K5065 (+1 more)
LEI:
Country:: United States of America
Address:: 6801 N CAPITAL OF TEXAS HIGHWAY, 78731 AUSTIN
Website:: https://www.cassavasciences.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cassava Sciences, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for Central Nervous System (CNS) disorders. The company's lead drug candidate is simufilam, a proprietary, investigational oral small molecule designed to modulate the activity of the filamin A (FLNA) protein, a key regulator in neuronal development. Cassava's primary development program is advancing simufilam as a potential therapy for tuberous sclerosis complex (TSC)-related epilepsy, supported by preclinical data showing a reduction in seizure activity. The company is also exploring the potential application of simufilam for other CNS indications.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all CASSAVA SCIENCES INC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CASSAVA SCIENCES INC

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for CASSAVA SCIENCES INC via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
MIMEDX GROUP, INC. Provides placental-based biologics for advanced wound care, surgical, and burn applications.	United States of America	MDXG
Mind Medicine (MindMed) Inc. Developing psychedelic-inspired medicines and novel therapies for brain health disorders.	United States of America	MNMD
Mineralys Therapeutics, Inc. Developing targeted treatments for hypertension & CKD driven by elevated aldosterone.	United States of America	MLYS
MiNK Therapeutics, Inc. Developing allogeneic iNKT cell therapies for cancer and immune-mediated diseases.	United States of America	INKT
MIRA PHARMACEUTICALS, INC. Develops novel ketamine and THC analogs for neurologic and neuropsychiatric disorders.	United States of America	MIRA
Mirum Pharmaceuticals, Inc. Develops and commercializes therapies for rare, debilitating liver diseases in children and adults.	United States of America	MIRM
Mithra Pharmaceuticals S.A. Biotech firm developing pharma for women's health: contraception, fertility, and menopause.	Belgium	MITRA
MIZUHO MEDY CO.,LTD. Develops rapid diagnostic tests & gene analyzers for clinical, research & agricultural markets.	Japan	4595
MOA Life Plus Co. Ltd. Develops immunotherapies & consumer solutions for immunity, skin rejuvenation, and pet care.	South Korea	142760
Moberg Pharma Develops & commercializes a leading topical treatment for nail fungus for European markets.	Sweden	MOB